Status: Recruiting
IIT2025-03-YANG-LIFT-HCC
The investigators are doing this study to learn if a combination of immunotherapy and a liver-directed tumor procedure can safely and effectively shrink or control liver cancer (hepatocellular carcinoma, HCC). The goal is to try to lower the stage of the cancer so that more patients may become eligible for a liver transplant. The investigators will also closely watch for side effects from the study treatments. Section 2 has more details.
Participants needed: 41
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Ju Dong YangUpdated: Mar 27, 2026Locations: 1
Eligibility criteria
Age ≥ 18 at the time of signing the Informed Consent Form. [+6]
1- Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed ch... [+2]